Cargando…

Cancer Pain Management: Opioid Analgesics, Part 2

Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding th...

Descripción completa

Detalles Bibliográficos
Autor principal: Wickham, Rita J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167083/
https://www.ncbi.nlm.nih.gov/pubmed/30310721
_version_ 1783360141890945024
author Wickham, Rita J.
author_facet Wickham, Rita J.
author_sort Wickham, Rita J.
collection PubMed
description Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity. Anticipation and proactive management of possible adverse effects, particularly constipation, confusion or delirium, opioid-specific adverse effects, and opioid abuse, are also integral to primary and secondary prophylaxis and management.
format Online
Article
Text
id pubmed-6167083
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-61670832018-10-11 Cancer Pain Management: Opioid Analgesics, Part 2 Wickham, Rita J. J Adv Pract Oncol Review Article Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity. Anticipation and proactive management of possible adverse effects, particularly constipation, confusion or delirium, opioid-specific adverse effects, and opioid abuse, are also integral to primary and secondary prophylaxis and management. Harborside Press 2017 2017-09-01 /pmc/articles/PMC6167083/ /pubmed/30310721 Text en Copyright © 2017, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Wickham, Rita J.
Cancer Pain Management: Opioid Analgesics, Part 2
title Cancer Pain Management: Opioid Analgesics, Part 2
title_full Cancer Pain Management: Opioid Analgesics, Part 2
title_fullStr Cancer Pain Management: Opioid Analgesics, Part 2
title_full_unstemmed Cancer Pain Management: Opioid Analgesics, Part 2
title_short Cancer Pain Management: Opioid Analgesics, Part 2
title_sort cancer pain management: opioid analgesics, part 2
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167083/
https://www.ncbi.nlm.nih.gov/pubmed/30310721
work_keys_str_mv AT wickhamritaj cancerpainmanagementopioidanalgesicspart2